In support of the oncogenic role, genetic ablation of CDC20 results in efficient tumor regression [103], while the loss of CDC20 inhibition promotes tumorigenesis [104], advocating CDC20 as a potential therapeutic target for cancer treatment [105]. This evidence concerns the gene CDC20 and cancer.